The reason for the jump is that they have had a favourable ruling in a dispute with BioNTech
TÜBINGEN, Germany/BOSTON, USA – March 27, 2025 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the European Patent Office (EPO) has confirmed the validity of CureVac’s European patent EP 3 708 668 B1 subject to amendments to specify the scope of protection. Following today’s hearing, the opposition division largely dismissed the opposition originally filed by BioNTech SE in April 2023 challenging the patent’s validity and maintained the patent in amended form.
The ruling represents a major milestone in the ongoing patent dispute between CureVac and BioNTech in Germany, which involves a total of six intellectual property rights. Following today’s ruling, the Regional Court Düsseldorf will decide whether the patent in its amended form has been infringed. An infringement hearing is scheduled for July 1, 2025. A positive infringement decision would trigger proceedings to assess damages in the same court.
https://markets.ft.com/data/announce/de ... 07878_en-1
If the next legal stages also go well for CureVac, I imagine the compensation from BioNTech could be huge.
[I'm holding but very underwater, had pretty much expected to be a loser in this one]